Business Context and Reporting Period
This Form 8-K is filed by First Light Acquisition Group, Inc. (not Calidi Biotherapeutics, Inc.) on September 13, 2022. The company is a Special Purpose Acquisition Company (SPAC) listed on the New York Stock Exchange. The filing reports on a special meeting of stockholders held on September 13, 2022, to approve an extension of the deadline to consummate a business combination.
Key Financial Metrics and Liquidity
- Trust Account Balance: Following stockholder redemptions, the Trust Account holds $41,562,580.79.
- Redemptions: Stockholders elected to redeem 18,871,976 shares of common stock.
- Shares Outstanding: Post-redemption, 4,128,024 shares remain issued and outstanding.
- Debt Issuance: The company issued two non-convertible unsecured promissory notes ("Extension Notes") totaling $490,000 ($366,233 to the Sponsor and $123,767 to Metric Finance Holdings I, LLC). These notes bear no interest and are repayable upon the consummation of a business combination.
- Revenue/Profit: The filing text does not provide revenue, profit, or operating margin data.
Material Changes Versus Prior Period
- Extension of Deadline: The date to consummate a business combination was extended from September 14, 2022, to December 14, 2022.
- Future Extension Rights: The Board now has the ability to extend the deadline up to three additional times for three months each (maximum 9 additional months), contingent on the Sponsor depositing 1% of the Trust Account balance per extension, unless a registration statement (Form S-4 or F-4) is already filed.
- Capital Structure Reduction: Significant reduction in outstanding shares due to the redemption of approximately 65.6% of the shares present at the meeting.
Guidance, Outlook, and Management Commentary
- Management Changes: Effective September 15, 2022, Thomas A. Vecchiolla was appointed co-Chief Executive Officer, serving alongside William J. Weber.
- Extension Fee Mechanism: Future extensions require a 1% fee from the Sponsor unless a merger registration statement is pending. If no deposit is made for a future extension, the Sponsor must deposit the 1% fee into the Trust Account.
- Use of Proceeds: Proceeds from the Extension Notes were used to fund the extension and for general working capital, subsequently deposited into the Trust Account.
- Risks: The company faces the risk of liquidation if a business combination is not consummated by the extended deadline (or further extensions).
Important Facts for Investor Verification
- Verify the exact remaining cash in the Trust Account ($41.56M) against the number of remaining shares (4.13M) to calculate the implied liquidation value per share.
- Confirm the terms of the Extension Notes and the obligation of the Sponsor to fund future extensions if a merger is not imminent.
- Review the status of any potential business combination targets, as the filing notes that no Extension Fee is required if a Form S-4 or F-4 is already filed.
- Monitor the new co-CEO leadership structure and its impact on deal execution.